Pharmacokinetics and Safety of Solid Oral Posaconazole (MK-5592, POS) in Chinese Subjects at High Risk for Invasive Fungal Infections
Phase of Trial: Phase I
Latest Information Update: 18 Jul 2017
At a glance
- Drugs Posaconazole (Primary)
- Indications Mycoses
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 26 May 2016 Status changed from active, no longer recruiting to completed.
- 04 May 2016 Planned End Date changed from 1 Apr 2016 to 1 May 2016.
- 04 May 2016 Planned primary completion date changed from 1 Apr 2016 to 1 May 2016.